Search Results
Your search for ,HOW matches 8288 pages
Showing 551 - 600CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC
Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...
NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers. The new guidelines followed the recent...
Tanning Bed Access, Usage May Be Driving Higher Rates of Melanoma in New England
Investigators have uncovered a potential link between the availability and use of tanning beds and the rising rates of melanoma in New England, according to a recent study published by Wei et al in the Journal of Investigative Dermatology. The findings may provide critical insights to inform public ...
Study Explores Underpinnings of Immunotherapy-Releated Myocarditis in Patients With Cancer
Researchers may have uncovered the immune basis for the development of myocarditis in patients with cancer receiving immune checkpoint inhibitors, according to a recent study published by Blum et al in Nature. The findings revealed changes in specific types of immune and stromal cells in the heart...
Breast Cancer in 2024: Looking Back and Moving Forward
In a recent issue of The New York Times, Barron Lerner discussed Betty Ford’s breast cancer diagnosis in 1974.1 He described the state of the art of breast cancer treatment at the time and how her diagnosis accelerated the uptake of screening across the country. But her cancer was not...
How Hypoxia May Help Cancer Metastasize
Researchers have identified genes that breast cancer cells may use to survive in the bloodstream after escaping the low-oxygen regions of a tumor, according to a novel study published by Godet et al in Nature Communications. Each of the genes may serve as a potential therapeutic target to prevent...
A Diagnosis of Lymphoma Has Changed My Life
I’m 50, just a year older than my father was when he died of colorectal cancer. I was 14 when my dad died, so to me, cancer has always been synonymous with death. From a young age, my brothers and I had a goal: to make sure we packed in enough life before age 50. It never occurred to us that death ...
From Gaps to Bridges: Cancer Care Rooted in Equity, Quality, and Value
“Inequities are a major obstacle in delivering safe, timely, respectful, and affordable cancer care globally,” commented moderator John Varallo, MD, MPH, FACOG, of the Global Surgery Foundation, at the Union for International Cancer Control (UICC) World Cancer Congress (WCC) 2024 in Geneva.1...
Study Finds Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost
The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, leading to a 144-fold increase in costs at the administrative level, impacting payer costs and patient cost-sharing amounts....
Physician Wellness and Professional Burnout
According to an ASCO-sponsored study of burnout and career satisfaction among U.S. oncologists, 44.7% of surveyed oncologists reported feeling symptoms of burnout. ASCO offers information, practical advice, and member perspectives on how to prevent and manage burnout and prioritize wellness in your ...
Tarlatamab-dlle for Previously Treated Extensive-Stage SCLC
On May 16, 2024, tarlatamab-dlle (Imdelltra) was granted accelerated approval for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager. Supporting Efficacy...
$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities
Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb...
When Cancer and Cardiovascular Disease Intersect
The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...
Evolving Role of MRD Status in Multiple Myeloma
The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...
Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings provided insights that could help advance...
Novel Method for Liquid Biopsies May Streamline Cancer Detection
Researchers have discovered a novel strategy to detect cancer cells with a liquid biopsy designed to be simpler, quicker, and more informational compared with current methods, according to a recent study published by Walker et al in Small. Background Current methods for detecting cancer cells may...
Quantifying the Benefit of Smoking Cessation Within 6 Months of a Cancer Diagnosis
Quitting smoking within 6 months of receiving a cancer diagnosis could add an average of 2 years to a patient’s life, according to a recent study published by Cinciripini et al in JAMA Oncology. The findings demonstrated a broad survival benefit of using evidence-based smoking cessation to help...
NCCN Harmonized Guidelines for Sub-Saharan Africa: Experts Convene in Ghana to Update Cancer Treatment Guidelines
An international team of oncology experts gathered in Accra, Ghana, for a series of meetings to update cancer treatment recommendations in the National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for Sub-Saharan Africa. Background The NCCN Harmonized Guidelines offer color-coded tiers ...
How End-of-Life Dreams and Visions Are Bringing Comfort to Dying Patients
Just weeks or even days or hours away from death, the majority of conscious terminally ill patients often experience growth and meaning in their lives and the absence of fear through end-of-life dreams and visions, according to research by Christopher W. Kerr, MD, PhD. Dr. Kerr is Chief Executive...
Weighing Blood-Based vs Standard Colorectal Cancer Screening Options
Because colonoscopies and more established stool-based tests are more effective at detecting early cancers and precancerous polyps compared with emerging blood-based tests, their long-term impact is projected to be substantially greater than that of blood-based tests, according to a recent study...
New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
Using computational tools, researchers have developed a novel method to assess which patients with metastatic triple-negative breast cancer may benefit from immunotherapy, according to a recent study published by Arulraj et al in the Proceedings of the National Academy of Sciences (PNAS)....
Ensuring an Inclusive Environment for Female Minority Oncologists
ASCO’s 2022 State of the Oncology Workforce in America report presented a dismal picture of the representation of Hispanic/Latinx oncologists in the field. According to the report, despite initiatives aimed at increasing diversity in the nearly 13,400 oncology workforce, which includes about 36%...
New Marker for Immunotherapy Response in Hepatocellular Carcinoma
A newly described stage of lymph node–like structures, known as tertiary lymphoid structures, identified in hepatic tumors following presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a recent study published by Shu et al in Nature...
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Mutations and DNA Structures May Drive Urothelial Carcinoma
Researchers may have uncovered how urothelial carcinoma originates and progresses, according to a novel study published by Nguyen et al in Nature. The findings provided insights into the biology of urothelial carcinoma and may point to new therapeutic strategies for this difficult-to-treat cancer...
My Melanoma Could Have Been Prevented
I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safety and maintaining annual full-body skin exams to catch any suspicious moles or lesions that could...
Whole-Person Cancer Care: A Transformative Vision for Oncology
Guest Editor’s Note: Advances in cancer treatments have led to an increase in survival rates, but the quality of life is often diminished during survivorship. Because modifiable personal behavior contributes to health-care outcomes, interventions that support healthy behaviors may improve health...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and “all-negative” subtypes.1...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Meeting the Long-Term Challenge of Achieving Equity in Global Cancer Care
Although significant progress has been made against cancer, especially in the United States, which has seen the overall death rate from cancer fall by 33% over the past 3 decades, translating into averting an estimated 3.8 million deaths from the disease,1 progress worldwide has not been as...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More, Part 2
In the October 10, 2024, issue of The ASCO Post, we shared some unique insights from several recipients of the international development and education award (IDEA). As oncologists and cancer researchers from diverse low- and middle-income countries, their experiences at the 2024 ASCO Annual Meeting ...
Raising Awareness of the Health Consequences of Alcohol Consumption During and After a Cancer Diagnosis
In 2023, the World Health Organization (WHO) declared that “no level of alcohol consumption is safe for our health.”1 The warning came decades after the International Agency for Research on Cancer classified alcohol as a Group 1 carcinogen, which is the highest risk group, and also includes...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Heart Failure and Cancer: New Insights Into Reciprocal Relationship
Investigators have highlighted a critical connection between heart failure and cancer, demonstrating how shared mechanisms may contribute to the incidence and progression of both diseases, according to a recent scientific statement published by Bloom et al in the Journal of Cardiac Failure....
Listening to Music May Accelerate Postsurgical Recovery
Listening to music may accelerate postsurgical recovery, according to recent findings presented by Raees et al at the American College of Surgeons (ACS) Clinical Congress 2024. Background “When patients wake up after surgery, sometimes they feel really scared and don’t know where they are,”...
Three Days Was Enough
My dad agreed to receive hospice on a technicality. It happened after weeks of trying to get him home oxygen. My brother drove him to the oncologist’s office, and I helped him get into the wheelchair. He did not complain, but just asked me to hold his coffee mug, smiling because I snuck him a...
Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
Head and Neck Cancer Clinical Trials May Be Becoming Less Diverse, Despite National Efforts
Many patients with head and neck cancer may lack equal opportunity to access experimental treatments in clinical trials or receive treatments that were shown to be effective in similar patients, according to a recent study published by Zuckerman and Edwards in Head & Neck. Background Millions...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
Patients With Multiple Sclerosis May Have an Increased Risk of Certain Types of Cancer
Some cancer types may be slightly more prevalent among patients with multiple sclerosis compared with those without the condition, according to a recent study published by Pierret et al in Neurology. Background In multiple sclerosis, the body’s immune system attacks myelin, the fatty white...
Julie Gralow, MD, FACP, FASCO, on Conserving IV Fluid Supplies During Natural Disasters
The nation’s intravenous fluid shortage was exacerbated this week when flooding from Hurricane Helene damaged a Baxter International plant in North Cove, North Carolina, which makes about 60% of the United States’ supply of fluids used in IVs for patients with a variety of diseases, including...
Novel Cell Therapy May Offer Benefit in Patients With Relapsed or Refractory T-Cell ALL
A novel cell therapy targeting CD7 on leukemia cells may provide an effective treatment option for patients with refractory T-cell acute lymphoblastic leukemia (ALL), according to a recent study published by Oh et al in Nature Medicine. The findings highlighted the effectiveness of a new chimeric...
Common Breast Cancer Treatments May Speed Aging Process
Researchers have found that common breast cancer treatments—including chemotherapy, radiation, and surgery—may accelerate the biological aging process among breast cancer survivors, according to a new study published by Carroll et al in the Journal of the National Cancer Institute. The findings...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...
Coping With the Risk of Hereditary Cancer
Three years ago, it had become clear that I needed to be tested for the BRCA1/2 mutation. I knew my family history of cancer was not good. My paternal grandmother died of breast cancer when she was just 41, and her mother had likely died of cervical cancer when she was in her 50s. More recently,...
Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...
Cancer Provider Groups Across the Country Urge Congress to Pass Prior Authorization Reform
The Association for Clinical Oncology (ASCO), along with 46 state oncology societies, sent a letter to U.S. House and Senate leadership urging Congress to pass the Improving Seniors’ Timely Access to Care Act (H.R. 8702/S. 4532), which would streamline prior authorization practices within Medicare...
AI Language Models May Generate Effective Physician's Letters
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics. Background According to recent surveys, physicians may spend almost 3 hours per day on documentation activities. “The...
Certain KRAS Gene Mutations Linked to Improved Prognosis in Pancreatic Cancer
A common mutation in the KRAS gene seems to be associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a recent study published in...
